oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Ghrelin is a prognostic marker and a potential therapeutic target in breast cancer
Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden .
Örebro University Hospital. Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden .
Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden.
Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden.
Show others and affiliations
2017 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 12, no 4, e0176059Article in journal (Refereed) Published
Abstract [en]

Ghrelin and obestatin are gastrointestinal peptides, encoded by the same preproghrelin gene. Both are expressed in breast cancer tissue and ghrelin has been implicated in breast cancer tumorigenesis. Despite recent advances in breast cancer management the need for new prognostic markers and potential therapeutic targets in breast cancer remains high. We studied the prognostic impact of ghrelin and obestatin in women with node negative breast cancer. Within a cohort of women with breast cancer with tumor size ≤ 50 mm, no lymph node metastases and no initiation of adjuvant chemotherapy, 190 women were identified who died from breast cancer and randomly selected 190 women alive at the corresponding time as controls. Tumor tissues were immunostained with antibodies versus the peptides. Ghrelin expression was associated with better breast cancer specific survival in univariate analyses (OR 0.55, 95% CI 0.36-0.84) and in multivariate models, adjusted for endocrine treatment and age (OR 0.57, 95% CI 0.36-0.89). Obestatin expression was non-informative (OR 1.2, 95% CI 0.60-2.46). Ghrelin expression is independent prognostic factor for breast cancer death in node negative patients-halving the risk for dying of breast cancer. Our data implies that ghrelin could be a potential therapeutic target in breast cancer treatment.

Place, publisher, year, edition, pages
2017. Vol. 12, no 4, e0176059
National Category
Cell and Molecular Biology Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-57319DOI: 10.1371/journal.pone.0176059ISI: 00399875200066PubMedID: 28419141Scopus ID: 2-s2.0-85017610426OAI: oai:DiVA.org:oru-57319DiVA: diva2:1103723
Note

Funding agencies:

Lion's Cancer foundation Swedish Cancer Society ETJ: CAN 2014/558 MLF: CAN 2011/461

Swedish Breast Cancer Association

Karlsson fund

Selanders foundation

Available from: 2017-05-30 Created: 2017-05-30 Last updated: 2017-10-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus
By organisation
Örebro University Hospital
In the same journal
PLoS ONE
Cell and Molecular BiologyCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 1 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf